NCT02085265

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Sunnybrook Health Sciences Centre · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting enzyme inhibitor (ACEI).

Detailed description

This study uses a simple validated measure of brain atrophy as a surrogate marker in a repurposing effort that could recast an antihypertensive medication as a cognitive enhancer/neuroprotective agent and possibly as a drug of choice for Alzheimer patients and patients at risk for AD. If the proof of concept result is positive, a larger study would be warranted with potential practice-changing impact.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	Perindopril	Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
DRUG	Telmisartan	Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)

Timeline

• Start date: 2014-03-01
• Primary completion: 2025-02-28
• Completion: 2025-02-28
• First posted: 2014-03-12
• Last updated: 2025-05-06

Locations

10 sites across 1 country: Canada